P210 Bcr-Abl interacts with the interleukin-3 βc subunit and constitutively activates Jak2

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Chronic myelogenous leukemia is a neoplasm of pluripotent hematopoietic cells. Cytokines such as interleukin-3 and granulocyte-macrophage colony-stimulating factor regulate the growth and differentiation of hematopoietic precursors. These cytokines activate two distinct signals to the nucleus. One signal is through the Ras pathway, and the second involves activation of Jak2. We demonstrated that Bcr-Abl co-immunoprecipitates with and constitutively phosphorylates the common βc chain of the interleukin-3 (IL-3) and granulocyte-macrophage-macrophage colony-stimulating factor (GM-CSF) receptors. Our data show that formation of this complex leads to the constitutive activation of Jak2. Previously, it has been demonstrated that Bcr-Abl interacts with Grb2 and She, which in turn activates the Ras pathway. Thus, Bcr-Abl can activate signalling through both pathways in a factor-independent fashion.

Original languageEnglish (US)
Pages (from-to)428-431
Number of pages4
Issue numberSUPPL. 3
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'P210 Bcr-Abl interacts with the interleukin-3 β<sub>c</sub> subunit and constitutively activates Jak2'. Together they form a unique fingerprint.

Cite this